<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">2675</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url">http://dx.doi.org/10.31782/IJCRR.2020.12096</article-id><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>Current Consensus on Drugs and Biologics against nCOVID-19 __ampersandsignmdash; __ampersandsignndash;__ampersandsignnbsp;A Systematic Review&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jain</surname><given-names>Rashmi</given-names></name></contrib><contrib contrib-type="author"><name><surname>SS</surname><given-names>Ajay</given-names></name></contrib><contrib contrib-type="author"><name><surname>Anudeep</surname><given-names>Talagavadi Channaiah</given-names></name></contrib><contrib contrib-type="author"><name><surname>Shetty</surname><given-names>Dharma U</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jeyaraman</surname><given-names>Madhan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chawla</surname><given-names>Aditi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mahajan</surname><given-names>Shivam</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tarunita</surname><given-names>Trisha</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>4</day><month>05</month><year>2020</year></pub-date><volume>)</volume><issue/><fpage>26</fpage><lpage>35</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>The deadly pandemic caused by the novel coronavirus continues to jeopardize humanity. The current situation report published by the World Health Organization (on1st May, 2020) confirms32,49,022 nCOVID-19 cases with 2,30,804 toll of human lives. This global statistical data reflects the contagiosity of SARS-CoV-2 across the world. This newly emerged strain has presented an unequalled challenge for identifying effective drugs __ampersandsignamp; biologics. Till date, no proven effective therapy exists for SARS-CoV-2 infection. The past experience of managing viral aetiological outbreaks renders background for extrapolation to nCOVID-19, yet effectivity remains uncertain. This dire scenario has been addressed with an escalation in the number of clinical trials in order to comeup with specific treatment. Repurposed drugs, Antibodies and Vaccines are under various stages of clinical trials currently. In the interim, supportive care, infection prevention measures and extended psychological assistance concords the core strategy to battle against this virus.&#13;
</p></abstract><kwd-group><kwd>Pandemic</kwd><kwd> World Health Organization</kwd><kwd> nCOVID-19</kwd><kwd> SARS-CoV-2</kwd><kwd> Effectivity</kwd></kwd-group></article-meta></front></article>
